CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase 2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer

CECs and IL-8 have prognostic and predictive utility in patients with recurrent platinum-sensitive ovarian cancer: biomarker correlates from the randomized phase 2 trial of olaparib and cediranib compared with olaparib in recurrent platinum-sensitive ovarian cancer

Objective: Olaparib (O), a PARP inhibitor, and cediranib (C), a VEGFR1-3 inhibitor together had greater activity than O alone in women with recurrent platinum-sensitive ovarian cancer (OvCa). The objective of this study is to identify potential lead biomarker candidates for response to O+C in the se...

Full description

Bibliographic Details
Main Authors: Jung-Min eLee, Jane B. Trepel, Peter eChoyke, Liang eCao, Tristan M Sissung, Nicole eHouston, Minshu eYu, William D Figg, Ismail eTurkbey, Seth M. Steinberg, Min-Jung eLee, Percy eIvy, Joyce eLiu, Ursula eMatulonis, Elise eKohn
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-06-01
Series:Frontiers in Oncology
Subjects:
biomarkers
ovarian cancer
IL-8
olaparib
CEC
Cediranib
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00123/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fonc.2015.00123/full

Similar Items